Compare BON & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BON | LEXX |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7M | 8.7M |
| IPO Year | 2020 | 2011 |
| Metric | BON | LEXX |
|---|---|---|
| Price | $1.22 | $3.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 7.0K | ★ 102.2K |
| Earning Date | 01-23-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $705,923.00 |
| Revenue This Year | $390.73 | N/A |
| Revenue Next Year | N/A | $601.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 52.05 |
| 52 Week Low | $0.98 | $0.35 |
| 52 Week High | $2.34 | $14.37 |
| Indicator | BON | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 57.73 | 36.66 |
| Support Level | $1.14 | $0.57 |
| Resistance Level | $1.22 | $12.89 |
| Average True Range (ATR) | 0.06 | 1.01 |
| MACD | 0.01 | -0.34 |
| Stochastic Oscillator | 87.82 | 8.56 |
Bon Natural Life Ltd focuses on the manufacturing of personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements by its customers. It has developed four technology platforms for large-scale separation, safety improvement, activity enhancement, and functional compounding of natural products. The company's offerings include Fragrance compounds, Health supplements, and Bioactive food ingredients. The company generates revenue from the sale of its products, the majority derived from the sale of Fragrance compounds, which include natural compounds extracted from plants for cosmetic applications.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.